Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Iasis Molecular
AddedFeb 16, 2024
UpdatedJun 18, 2026
Iasis Molecular

Iasis Molecular

Pre-Seed

Spokane-based software company, Iasis Molecular Sciences & Novion Technologies, innovates cost-effective antimicrobial technologies to combat healthcare-acquired infections and promote healing.

HQ
Spokane, WA, US
Founded
2008
Overview
Compare
Fundraising
Employees
Website

Iasis Molecular focuses on developing innovative chemistries to address human health and habitat challenges. The company specializes in creating solutions to impede the transmission of bacterial, fungal, and viral diseases, with a particular emphasis on combating healthcare-associated infections. Their work extends to patient protection and eco-sustainable solutions for everyday life, addressing the critical issue of antimicrobial resistance.

Based in Spokane, Washington, Iasis Molecular has pioneered and patented a family of technologies aimed at minimizing healthcare-acquired infections related to implantable medical devices, surgical procedures, and chronic wounds. Their proprietary antimicrobial agent technologies are designed to be cost-effective and accessible, potentially benefiting patients across diverse demographics and medical needs.

Iasis Molecular - Quick Facts

When was Iasis Molecular founded?

Iasis Molecular was founded in 2008.

Where is Iasis Molecular's headquarters located?

Iasis Molecular's headquarters is located in Spokane, WA, US.

When was Iasis Molecular's last funding round?

Iasis Molecular's most recent funding round was for $1.3M (USD) in January 2022.

How much has Iasis Molecular raised to-date?

As of Jan 25, 2022, Iasis Molecular has raised a total of $1.3M (USD).

How many employees does Iasis Molecular have?

Iasis Molecular has 3 employees as of Feb 4, 2024.

Iasis Molecular - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antimicrobial
  • Healthcare
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software